{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:13:49Z","timestamp":1789445629385,"version":"build-2803163510"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Clin Cancer Inform"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Nivolumab plus ipilimumab (NIVO + IPI) is a first-in-class combination immunotherapy for the treatment of intermediate- or poor (I\/P)-risk advanced or metastatic renal cell carcinoma (mRCC). Currently, there are limited real-world data regarding clinical effectiveness beyond 12-24 months from treatment initiation. In this real-world study, treatment patterns and clinical outcomes were evaluated for NIVO + IPI in a community oncology setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>A retrospective analysis using electronic medical record data from The US Oncology Network examined patients with I\/P-risk clear cell mRCC who initiated first-line (1L) NIVO + IPI between January 4, 2018, and December 31, 2019, with follow-up until June 30, 2022. Baseline demographics, clinical characteristics, treatment patterns, clinical effectiveness, and safety outcomes were assessed descriptively. Overall survival (OS) and real-world progression-free survival (rwPFS) were analyzed using Kaplan-Meier methods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Among 187 patients identified (median follow-up, 22.4 months), with median age 63 (range, 30-89) years, 74 (39.6%) patients had poor risk and 37 (19.8%) patients had Eastern Cooperative Oncology Group performance status score \u22652. Of 86 patients who received second-line therapy, 54.7% received cabozantinib and 10.5% received pazopanib. The median (95% CI) OS and rwPFS were 38.4 (24.7-46.1) months and 11.1 (7.5-15.0) months, respectively. Treatment-related adverse events (TRAEs) were reported in 89 (47.6%) patients, including fatigue (n = 25, 13.4%) and rash (n = 19, 10.2%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>This study provides data to support the understanding of the real-world utilization and long-term effectiveness of 1L NIVO + IPI in patients with I\/P-risk mRCC. TRAE rates were low relative to clinical trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/cci.24.00132","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T21:00:21Z","timestamp":1734728421000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":10,"title":["Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States"],"prefix":"10.1200","author":[{"given":"Gurjyot K.","family":"Doshi","sequence":"first","affiliation":[{"name":"Texas Oncology, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4488-0604","authenticated-orcid":true,"given":"Andrew J.","family":"Osterland","sequence":"additional","affiliation":[{"name":"Ontada, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Shi","sequence":"additional","affiliation":[{"name":"Ontada, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Yim","sequence":"additional","affiliation":[{"name":"Ontada, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Del Tejo","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Guttenplan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8612-3807","authenticated-orcid":true,"given":"Samantha","family":"Eiffert","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Conkling","sequence":"additional","affiliation":[{"name":"Ontada, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program: Cancer Stat Facts Kidney and Renal Pelvis 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15922-4"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.46"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70559-4"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_3_5_10_2","unstructured":"US Food and Drug Administration: FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. 2018. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-combination-intermediate-or-poor-risk-advanced-renal-cell"},{"key":"e_1_3_5_11_2","unstructured":"US Food and Drug Administration: FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. 2019. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma"},{"key":"e_1_3_5_12_2","unstructured":"US Food and Drug Administration: FDA approves avelumab plus axitinib for renal cell carcinoma. 2019. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-avelumab-plus-axitinib-renal-cell-carcinoma"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.363"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.01.001"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294039"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.12.015"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.12.003"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac195"},{"key":"e_1_3_5_19_2","unstructured":"The US Oncology Network: Our Company. https:\/\/usoncology.com\/our-company\/"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34180"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","unstructured":"Geynisman DM Faccone J Zhang Y et al: Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data. Journal of Clinical Oncology. Volume 39 Number 6_suppl.","DOI":"10.1200\/JCO.2021.39.6_suppl.288"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0156-8"}],"updated-by":[{"DOI":"10.1200\/cci-25-00026","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000}}],"container-title":["JCO Clinical Cancer Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/CCI.24.00132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:01:30Z","timestamp":1741183290000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/CCI.24.00132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1200\/CCI.24.00132"],"URL":"https:\/\/doi.org\/10.1200\/cci.24.00132","relation":{"correction":[{"id-type":"doi","id":"10.1200\/CCI-25-00026","asserted-by":"object"}]},"ISSN":["2473-4276"],"issn-type":[{"value":"2473-4276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400132"}}